Live Currency Rates
 
  Quotes: US MENA   Enter Symbol: NewsLetter: Search: advanced

Resonance Health receives FDA authorisation for FerriScan  Join our daily free Newsletter

MENAFN - ProactiveInvestors - Australia - 27/01/2013

No. of Ratings : 0
Add to Mixx!


 


(MENAFN - ProactiveInvestors - Australia) Resonance Health's (ASX: RHT) FerriScan technology has been authorised by the U.S. Food and Drug Administration to be marketed as an imaging companion diagnostic device for use of Exjade in patients with non-transfusion-dependent thalassemia (NTDT).

Exjade is a drug marketed by Novartis to remove excess iron in patients with genetic blood disorders.

The FDA said in a statement "the FerriScan device is a non-invasive test that helps physicians to select appropriate patients [with NTDT] for Exjade therapy as well as monitor their response to the drug."

It is known that over three quarters of a million people worldwide have non-transfusion-dependent thalassemia (NTDT) and many patients are not diagnosed until they develop serious symptoms which begin to appear as early as age 10.

Most patients with NTDT are of South and Southeast Asian, Mediterranean or Middle Eastern origin, with immigration broadening the global presence of this condition.

FerriScan has been used extensively in the clinical trials of pharmaceutical companies developing drugs for chronic iron overload since 2004.

This FDA announcement of FerriScan as a companion diagnostic for the safe and effective use of a drug recognises its importance in the clinical management of patients outside of clinical trials.

FerriScan is currently used in many hospitals around the world and this authorisation by the FDA will assist in expanding the use of FerriScan in the identification and management of patients with iron overload.

It will also assist in the Company's efforts to gain insurance coverage for FerriScan within the US, enabling more patients to access FerriScan.

The company also said it does not have details concerning how often a patient with NTDT and prescribed Exjade will require a measurement of their liver iron concentration.

 






  MENA News Headlines


 






Google

 
 

Middle East North Africa - Financial Network

MENAFN News Market Data Countries Tools Section  
 

Middle East North Africa - Financial Network
Arabic MENAFN

Main News
News By Industry
News By Country
Marketwatch News
UPI News
Comtex News

IPO News
Islamic Finance News
Private Equity News

How-To Guides
Technology Section

Travel Section

Search News

Market Indices
Quotes & Charts

Global Indices
Arab Indices

US Markets Details

Commodoties

Oil & Energy

Currencies Cross Rates
Currencies Updates
Currency Converter

USA Stocks
Arab Stocks
 

Algeria 
Bahrain 
Egypt 
Iraq
Jordan 
Kuwait 
Lebanon
Morocco 
Oman 
Palestine
Qatar 
Saudi Arabia 
Syria
Tunisia 
UAE 
Yemen

Weather
Investment Game
Economic Calendar
Financial Glossary

My MENAFN
Portfolio Tracker

Voting

Financial Calculators

RSS Feeds [XML]

Corporate Monitor

Events

Real Estate
Submit Your Property

Arab Research
Buy a Research

Press Releases
Submit your PR

Join Newsletters


 
© 2000 menafn.com All Rights Reserved.  Terms of Service | Privacy Policy | Contact Us | Advertise | About MENAFN | Career Opportunities | Feedback | Help